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The Role of Thymic Stromal Lymphopoietin (TSLP) in 
Glomerulonephritis 
Thymic stromal lymphopoietin (TSLP) is an interleukin-7-like cytokine that is an 
important trigger and initiator of many allergic diseases. TSLP promotes a T-helper 
type 2 (Th2) cytokine response that can be pathological. A relationship is formed 
both at the induction phase of the Th2 response through polarization of dendritic 
cells to drive Th2 cell differentiation and at the effector phase of the response, by 
promoting the expansion of activated T cells and their secretion of Th2 cytokines 
and TSLP.  In transgenic mice with TSLP overexpression, it has been reported that 
TSLP leads to the development of mixed cryoglobulinemic membranoproliferative 
glo merulonephritis. In addition, TSLP can play an important role in the pathoge-
nesis of IgA nephropathy and systemic lupus erythematosus-related nephritis. 
From our knowledge of the role of TSLP in the kidney, further studies including the 
discovery of new therapies need to be considered based on the relationship bet-
ween TSLP and glomerulonephritis.
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Introduction
 
Thymic stromal lymphopoietin (TSLP), an interleukin (IL)-7-like cytokine, 
has been reported in several studies about multiple diseases such as allergic 
air way disease1), atopic skin disease2), inflammatory bowel disease (IBD)3,4), 
or even breast5) and pancreatic cancer6). Even though glomerulonephritis 
inclu ding membranoproliferative glomerulonephritis (MPGN) remains an 
un solved kidney disease for clinicians until now, however, there have been 
few reports of TSLP especially in the pathogenesis of glomerulonephritis.  
In this review, we will focus on understanding the role of TSLP-related to 
unknown mechanism of glomerulonephritis and discuss the potential of 
TSLP in glomerulonephritis pathogenesis as a therapeutic manner.
TSLP in relation to Th2 cytokines
TSLP can induce about dendritic cells (DCs)-mediated T-helper type 2 (Th2) 
inflammatory responses7). It is a trigger and initiator for many allergic diseases 
and it promotes Th2 cytokine responses that can be either host protective or 
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pathological8). A relationship is shown both at the induc-
tion phase of the Th2 response through polarization of DCs 
to drive Th2 cell differentiation and at the effector phase of 
the response by promoting the expansion of activated T 
cells and their secretion of Th2 cytokines9). TSLP can drive 
a Th2 cytokine response, potentially through effects on 
DCs, especially10). After stimulated by TSLP, the dendritic 
cell activates CD 4+ T cells leading to T cell proliferation11). 
In the absence of IL-12, dendritic cells induce expression of 
OX40L, the ligand for the cell survival factor OX40, OX40- 
OX40L interactions are critical for the ability of the DCs to 
drive Th2 cell differentiation12). 
TSLP also seems to promote basophil responses. Influen-
cing cytokine expression in DCs, the Th2 promoting pro-
perties of TSLP may be mediated through basophils13). 
Basophils enhance the Th2 response and impair the Th1 
response. Basophils can develop Th2 cells in vitro and in 
vivo by producing Th2 cytokines such as IL-4 and IL-13. 
In this part of view, TSLP plays an important role in the 
pathogenesis of atopic dermatitis and asthma14). TSLP in-
duces upregulation of OX40L expression on DCs cells. Th2 
cytokines released, including IL-4, IL-5, IL-9, IL-13, bind 
to their receptors and activate inflammatory and structural 
cells involved in the pathogenesis of asthma15). TSLP is 
overtly expressed on skin lesions of atopic derma titis. T 
cells from atopic dermatitis patients possess strong potential 
to directly interact with TSLP to promote a Th2 response16). 
So, TSLP is a good therapeutic target in the treatment of 
allergic diseases, but its protective role in in flammatory 
bowel disease (IBD) is an important caution because neu-
tralization of TSLP could potentially unmask or aggravate 
Th17 and or Th2 dominated inflammatory disease14). 
TSLP transgenic mice and membranoprolife­
rative glomerulonephritis (MPGN)
Membranoproliferative glomerulonephritis (MPGN) is 
an intractable kidney disease of unknown etiology which 
can be developed in children and young adults with features 
of nephrotic or nephritic syndrome17). Renal dysfunction 
occurs frequently with rapid progression in MPGN17). 
MPGN in children is mostly idiopathic, whereas MPGN 
in adults is commonly associated with cryoglobulinemia18) 
or hepatitis C virus infection19) which can be shown as the 
glomerular injury of cryoglobulinemic MPGN. The me-
chanism of the deposition and the role of cryoglobulins in 
the kidney are unclear.
Mice transgenic for TSLP, under regulation of the lym-
phocyte-specific promotor lymphocyte protein tyrosine 
kinase (Lck), develop cryoglobulinemia and MPGN similar 
to the disease in patients. In 2001, Taneda et al. firstly pre-
sented transgenic mouse model of mixed cryoglobuline-
mia20). This in vivo mouse model sug gested that severe 
glomerular lesions were shown in patho logic findings, but 
the tubulointerstitium was intact com pared to glomerular 
areas20). They also found the pathologic findings such as 
capillary wall thickening, subendothelial immune-deposi-
tion, mesangium expansion, double con tours of the base-
ment membrane, which resemble MPGN findings in hu-
man kidney20). 
It is estimated that overexpression of TSLP in mice results 
in the development of mixed cryoglobulinemic MPGN. In 
TSLP transgenic mice with overexpression, cryoprecipitates 
are mixed type composed of IgG, IgM and light chains20). 
In glomerular deposits, IgG, IgM, IgA and complement C3 
are detected distinctively compared to C3 deposition that 
was detected in glomeruli from wild-type20). These patho-
logic features closely resemble the pathologic features of 
human cryoglobulinemic MPGN20). Therefore, TSLP-trans-
genic mice are a very attractive MPGN model and enable 
to study pathogenesis of human MPGN.
After development of TSLP transgemic mice, there were 
many studies using these animals to reveal the pathogenesis 
of MPGN. Segerer et al. tested oral interferon (IFN)-alpha 
(used as treatment in humans with cryoglobulinemic 
glomerulonephritis) in 41 TSLP transgenic mice21). It was 
shown that IFN-alpha affected reducing influx of glome-
rular macrophage in contrast to little effect on the glome-
rular matrix deposition21). They also suggest that IFN-alpha 
therapy can have some antiviral effects in TSLP transgenic 
mice21). And transforming growth factor (TGF)-β1 protein 
increased when mesangial cells are stimulated with cryo-
globulin in vitro21). So it is concluded that cryoglobulins 
directly upregulate protease nexin (PN)-1, plasminogen 
activator inhibitor (PAI)-1 and TGF- β1 which are impor-
tant mediators of glomerulonephritis21).
In 2003, Mühlfeld et al. engaged immunoglobulin-binding 
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receptors (FcγRIIb) on leukocytes categorizing four mice 
groups: wild-type, FcγRIIb-/-, TSLP transgenic, and com-
bined TSLP transgenic/ FcγRIIb-/- mice22). TSLP transgenic 
mice with knock out of FcγRIIb led to a significant aggra-
vation of the immune complex-mediated renal disease and 
decreased renal function and increase in proteinuria. TSLP/ 
FcγRIIb -/- mice had significantly increased glomerular 
size due to an increase in glomerular extracellular matrix 
and glomerular cellularity22). Increased glomerular cellu-
larity was due to an increase in proliferating glomerular 
cells and infiltration of monocytes/macrophage22). Also, 
FcγRIIb defect mice with TSLP overexpression showed 
upregulation of PN-1 and PAI-122). The study showed that 
FcγRIIb-/- mice had no significant renal pathology whereas 
TSLP transgenic FcγRIIb-/- mice showed significantly im-
paired glomerular lesions with decreased kidney function 
and high mortality22). FcγRIIb was revealed to regulate 
immune responses and have possibilities as a useful the-
rapeutic target for glomerular diseases22). PAI-1 was pre-
viously studied in various renal models, leading to renal 
fibrosis and renal failure23,24). PAI-1 and PN-1 expression 
was strong in mesangial matrix in TSLP transgenic mice 
and further increased in TSLP/FcγRIIb -/- mice25).
Banas et al. analyzed the level of toll-like receptors (TLR) 
in TLSP transgenic mice26). In TSLP transgenic mice, TLR 
subtype 1, 2, and 4 were increased and even higher in TSLP/ 
FcγRIIb -/- murine kidney26). Especially TLR4 was overex-
pressed in mature podocytes in vivo and in vitro26). In 
MPGN of TSLP/FcγRIIb -/- mice, TLR4 in podocytes may 
have a potential role in inflammatory reaction by respon-
ding to foreign bodies like pathogens or endogenous ligand 
like fibrinogens and recruiting inflammatory cells in glo-
merulonephritis26). In other words, TLR4 may act as a link-
age of the innate immune system and glomerular injury 
triggered by elevated immune complexes26). 
In another study, Mühlfeld et al. crossbred TSLP trans-
genic mice with overexpressing Crry (complement receptor- 
1 related gene/protein Y)27). There was no significant im-
provement of glomerulus in TSLP/Crry doubly transgenic 
mice suggesting that overexpressing Crry was not sufficient 
to suppress TSLP activation27). Iyoda et al. tested all-trans-
retinoic acid (ATRA), a powerful anti-inflammatory agent, 
on TSLP transgenic mice28). Similar to Crry, ATRA does 
not protect aggravation of cryoglobulinaemic MPGN and 
thus retinoid therapy has to be used with caution28). 
Guo et al. developed TSLP transgenic mice expressing 
the human diphtheria toxin receptor (DTR) mice (Lck-
TSLP; CD11b-DTR) to control and ablate the monocyte/
macrophage-restricted CD11b promoter29). In this mouse 
model, suppression of macrophage showed protective ef-
fects on the disease progression in cryoglobulinemic MPGN 
29). Astrakhan et al. developed an in vivo K5-TSLP (doxy-
cycline-inducible, keratin 5–driven transgene encoding 
TSLP) transgenic mouse model30). In this model, immature 
B cells were increased in periphery with expansion of folli-
cular mature B cells meaning activation of systemic B cell 
development30). This finding suggests that expression of 
TSLP is closely related to systemic humoral autoimmunity30).
TSLP and other glomerulonephritis 
Although studies about TSLP are mainly dependent upon 
MPGN, there are two studies about IgA nephropathy and 
systemic lupus erythematosus (SLE)-related nephritis. 
Meng et al. found out that both the serum level of TSLP and 
the numbers of IgA-bearing cells were increased in IgA 
nephritis patients31). Overexpression of TSLP may enhance 
IgA class switching correlated with activation-induced 
cytidine deaminase (AID), TGF-β1, B cell-activating factor 
of the tumor necrosis factor family (BAFF), and a prolife-
ration-inducing ligan (APRIL) in tonsillar follicular dend-
ritic cells (FDC) and result in IgA deposition in the renal 
mesangium31). Ellison et al. used palifermin (recombinant 
human keratinocyte growth factor, also known as fibroblast 
growth factor-7) in acute or chronic GVHD mouse model 
which resembles pathologic findings of glomerular lesion 
in SLE32,33). Both palifermin-treated and untreated mice 
were shown pathological injuries in the kidney, but these 
changes in palifermin-treated recipients resemble those 
seen in TSLP transgenic mice32). They hypothesized that 
overexpression of TSLP was induced by treating palifermin 
and is closely related to GVHD or SLE nephritis32). 
Concluding remarks and future perspectives
We try to demonstrate that TSLP, a Th2-like cytokine, 
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could affect pathogenesis of MPGN by changing the podo-
cytes in animal and human model. TSLP stimulates my-
eloid dendritic cells (mDC), which express the TSLP re-
ceptor. TSLP-activated mDC can promote naïve CD4+ T 
cells to differentiate into a Th2 phenotype and can trigger 
the expansion of CD4+ Th2 memory cells. 
To summarize, TSLP can be an important cytokine to 
develop glomerulonephritis. Through previous studies, 
pathogenesis of glomerulonephritis has been clarified using 
TSLP-transgenic mice. It is also proposed that we could 
clarify whether TSLP is involved in the pathogenesis of 
glomerulonephritis by injecting TSLP to mice with gradu-
ally increasing concentration or if we can make an animal 
model which express podocyte-specific TSLP. Based on the 
results about the relationship between TSLP and glomeru-
lonephritis, the new therapy could be invented based on the 
hypothesis that suppression of TSLP signaling improves 
glomerulonephritis in mice and in the human model by 
regulating dendritic cell-mediated T-helper type 2 inflam-
matory responses. 
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